WA
GNCA

Wasatch Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

Wasatch Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-12,378
Closed -$517K – 355
2017
Q2 		$517K Hold
12,378
– – 0.01% 319
2017
Q1 		$603K Buy
+12,378
New +$484K 0.01% 317

Other funds holding GNCA

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return

Wasatch Advisors's GNCA Position: Q3 2017 in Review

Wasatch Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2017, closing a stake of 12,378 shares — an estimated $517K sold.

Wasatch Advisors first reported a position in GNCA in Q1 2017 and held it in 2 quarters. The position peaked at $603K in Q1 2017. 62 funds tracked by Wall St. Rank hold GNCA as of Q3 2017.

  • Wasatch Advisors reported no remaining Genocea Biosciences, Inc. position as of Q3 2017 after selling out during the quarter.
  • Wasatch Advisors sold 12,378 Genocea Biosciences, Inc. shares in Q3 2017, an estimated $517K.
  • Wasatch Advisors first reported a position in Genocea Biosciences, Inc. in Q1 2017 and held it in 2 quarters.
  • Wasatch Advisors's Genocea Biosciences, Inc. position peaked at $603K in Q1 2017.
  • 62 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2017.

Based on Wasatch Advisors's 13F filing for Q3 2017, filed 8 Nov 2017.